MDX Limo
ClinicOS Blueprint — Core Theory v0.1

ClinicOS Blueprint — Core Theory v0.1

A one-page hypothesis document. Living. Updated after every wave.

The bet

The independent peptide clinic — 1 to 3 locations, cash-pay, already injecting — is operating with a stack that wasn't built for them. They're stitching together a compounding pharmacy contact, a generic EHR, a booking tool, an email platform, and a marketing agency they don't trust. The supply is unreliable, the marketing is non-compliant, and the operator is the bottleneck.

ClinicOS is the rail underneath all of it. Supply, software, and patient pipeline in a single integrated system. Shopify for 503A peptide clinics. Own the rail, then own the consumer.

The customer

Independent clinics, 1–3 locations, owner-operated, cash-pay native, currently prescribing or ready to prescribe peptides.

Priority sequence: med spas first (highest intent, injectable-native, fastest close), then OBGYN/women's hormone clinics (largest script volume), then men's hormone clinics (TRT adjacency). Primary care, internal medicine, sports medicine come later — too much educational lift for launch.

Hard filter: skip anything with a board, PE backing, or 4+ locations. Wrong cycle time for a design partner program.

The problem (hypothesis — to be replaced with verbatim from the field)

"I want to add peptides — or grow the peptide side I already have — but my supply is unreliable, I can't legally market them the way I'd want to, and I'm spending hours a week on operations that don't make me money."

This is our straw-man. Wave 1's job is to tear it down and replace it with the real version, in clinics' actual language.

The WOW features (ranked, to be validated)

  1. The 503A rail. Compliant doctor-collects-then-pays-platform transaction flow. Drop-ship to patient. Multiple pharmacy backends. This is the wedge.
  2. The marketing engine. Done-for-you, FDA/FTC-compliant ad creative, landing pages, lead-gen for the clinic. This is the retention lever — clinics don't churn from the thing generating their patient pipeline.
  3. The MLM referral layer. Reps recruit clinics, clinics recruit clinics, commissions flow up. Distribution that compounds.
  4. EMR module (v3). Roadmap, not v1. Tightens the moat once we have density.

The pitch

"We're Shopify for 503A peptide clinics. We give you a compliant supply chain, a marketing engine that brings you patients, and a referral layer that pays you when other clinics join. You keep practicing medicine. We run the rail."

The pricing (hypothesis)

  • Per-script economics: clinic keeps ~200of200 of 400, pharmacy gets ~50,ClinicOSnets50, ClinicOS nets 30–50.
  • SaaS layer: 1,500/mostandardtier,1,500/mo standard tier, 3,000/mo with marketing engine bundled. Test both.
  • Pharmacy partner rev share: 8–12% target.
  • 50% off for 6 months + 12-month price lock for design partners.

The unfair advantage (3 sources, at least one must hold)

  1. Supply. Raja / Vesalius Labs anchor + 2–3 backup compounding pharmacies. Without this we don't ship.
  2. Engineering velocity. Modern AI-assisted dev means we ship in weeks what competitors ship in quarters. Software quality + design taste as competitive moat.
  3. Marketing engine. The compliance-aware ad system is the hardest thing for competitors to copy, and the stickiest thing for clinics.

We need to validate which of these is truly unfair. Suspect: supply is replicable, engineering is real but doesn't compound, marketing engine is the durable moat.

The GTM

Outbound-led, founder-sold, design-partner-first.

  • Top of funnel: Ed runs personalized outbound to 100 ICP clinics in Wave 0. Email + LinkedIn.
  • Discovery: Alton runs 30–45 min discovery calls. Open-ended, voice-extraction.
  • Clinical close: Raja or designee handles the technical/clinical objections in stage 2.
  • Contract close: Alton lands LOI, then onboarding.

Future: MLM rep layer turns the GTM motion into a self-replicating distribution engine. Not v1 — v1.5.

What we're racing against

A competitor 3–4 weeks ahead on product with sales muscle already in market. They're a distribution play; we're a platform play. Speed matters but quality matters more — they will pick off fast clinics on price, we win the durable ones on software + marketing.

The 6-month window: market gets crowded by Q4. We need to be the obvious choice in the design-partner cohort by then.

The validation gate

7 of 10 prospects in the upper-right quadrant (Relevance ≥ B, Willingness ≥ B) by end of Wave 3. That's the green light to scale: hire engineers, raise the seed, turn on the marketing engine.

If we don't hit it, the rail isn't broken — the Blueprint is. Iterate before we deploy capital.

What we still don't know (the call agenda for Waves 1–3)

  • What clinics actually call the problem in their own words
  • Whether the 200/200/50/$50 split holds when they see real numbers
  • Whether marketing engine is must-have or nice-to-have
  • What buying trigger makes them sign this quarter vs someday
  • What stack they're replacing — and what they'll insist we integrate with
  • Whether the clinical-close handoff (Ed → Raja → Alton) actually converts

Last updated: April 25, 2026. Revisions tracked weekly after each wave debrief.

Created with MDX Limo
ClinicOS Blueprint — Core Theory v0.1 | MDX Limo